

GSK Pharma

Estimate change



TP change



Rating change


CMP: INR2,018
TP: INR2,170 (+8%)
Neutral

Flagship brands/innovative products drive operational performance

Launch of cancer drugs on the cards in 1HFY26

- GlaxoSmithKline Pharmaceuticals (GLXO) delivered a better-than-expected performance in 3QFY25, largely driven by robust volume growth in the general medicine segment and a continued scale-up in vaccine offtake. Notably, GLXO strengthened its market share in top brands like Augmentin, Ceftum and T-bact. It also expanded its presence for its respiratory products.
- We raise our earnings estimates by 2%/5%/7% for FY25/FY26/FY27 to factor in a) differentiated launches in cancer therapy, b) scale-up of vaccine business, c) enhanced efforts to boost vaccine prospects. We value GLXO at 33x 12M forward earnings to arrive at a TP of INR2,170.
- Compared to a 9% EBITDA CAGR over FY22-24, we expect GLXO to deliver a 19% EBITDA CAGR over FY25-27, driven by niche launches, market share gain, and enhanced reach. In addition to vaccines, GLXO would also be introducing innovative drugs to treat endometrial and ovarian cancer. However, the current valuation captures the earnings upside. Maintain Neutral.

Product mix and improved productivity boost margins YoY

- Revenue grew 17.9% YoY to INR9.5b (est: INR8.5b).
- Gross margin (GM) contracted 150bp YoY to 62.2%, due to a change in the product mix.
- There was a one-off gain of INR90m in employee expenses due to lower incentives for some brands.
- Adjusting the one-off item, EBITDA margin expanded 270bp YoY to 29.7% (our est: 29.2%) due to lower employee expenses (down 350bp YoY as % of sales), offset by higher other expenses (up 230bp as a % of sales).
- EBITDA grew 29.8% YoY to INR2.8b (vs. est. of INR2.5b).
- Adj. PAT grew 5.7% YoY to INR2.2b for the quarter (our est. INR1.9b).
- For 9MFY25, revenue/EBITDA/PAT grew by 10%/28%/20% YoY to INR27.7b/INR8.4b/INR6.6b.

Key highlights from the management commentary

- GLXO would be launching two assets in the gynec cancer segment (endometrial cancer and ovarian cancer) in India in 1HFY26.
- It is implementing efforts to build an ecosystem for adult vaccination through educating healthcare practitioners.
- GLXO is making efforts to sustain EBITDA margin going forward.
- The company reported volume growth of 11% YoY and price hike of 3% YoY for 3QFY25 in the general medicine category.
- Paed Vaccines portfolio grew 14% YoY, led by Boostrix, Varilrix, and Havrix.
- Field productivity improved by 27% during 9MFY25.

Bloomberg	GLXO IN
Equity Shares (m)	169
M.Cap.(INRb)/(USDb)	341.9 / 3.9
52-Week Range (INR)	3074 / 1817
1, 6, 12 Rel. Per (%)	-2/-23/-11
12M Avg Val (INR M)	371

Financials & valuations(INR b)

Y/E MARCH	FY25E	FY26E	FY27E
Sales	37.5	41.6	46.6
EBITDA	11.1	12.9	14.8
Adj. PAT	8.7	10.0	11.7
EBIT Margin (%)	27.9	29.1	30.2
Cons. Adj. EPS (INR)	51.3	59.0	69.0
EPS Gr. (%)	18.4	15.1	16.9
BV/Sh. (INR)	128.9	160.3	201.7

Ratios

Net D:E	-0.5	-0.6	-0.7
RoE (%)	39.8	36.8	34.2
RoCE (%)	43.9	40.9	38.1
Payout (%)	56.3	48.9	41.9

Valuations

P/E (x)	39.5	34.3	29.4
EV/EBITDA (x)	30.1	25.6	21.9
Div. Yield (%)	1.2	1.2	1.2
FCF Yield (%)	1.3	2.8	3.2
EV/Sales (x)	8.9	7.9	6.9

Shareholding pattern (%)

As On	Dec-24	Sep-24	Dec-23
Promoter	75.0	75.0	75.0
DII	7.3	7.3	8.7
FII	4.5	4.4	2.9
Others	13.2	13.3	13.4

FII Includes depository receipts

Tushar Manudhane - Research Analyst (Tushar.Manudhane@MotilalOswal.com)

Research Analyst - Akash Manish Dobhada (Akash.Dobhada@MotilalOswal.com) | Viraj Shah (Viraj.Shah@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

Qtr Perf. (Consol.)

(INR m)

Y/E March	FY24				FY25E				FY24	FY25E	FY25E	Chg.
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE			3QE	(%)
Net Sales	7,617	9,570	8,053	9,298	8,147	10,107	9,494	9,719	34,537	37,467	8,492	12%
YoY Change (%)	2.2	4.4	0.4	18.1	7.0	5.6	17.9	4.5	6.2	8.5	5.5	
Total Expenditure	6,178	6,675	5,872	6,725	5,841	6,891	6,665	6,930	25,450	26,326	6,012	
EBITDA	1,439	2,895	2,181	2,573	2,305	3,216	2,829	2,790	9,087	11,141	2,480	14%
YoY Change (%)	-3.4	12.7	-4.7	51.6	60.2	11.1	29.7	8.4	13.0	22.6	13.7	
Margins (%)	18.9	30.3	27.1	27.7	28.3	31.8	29.8	28.7	26.3	29.7	29.2	
Depreciation	164	181	171	181	164	169	188	175	697	696	178	
EBIT	1,276	2,714	2,010	2,392	2,141	3,048	2,641	2,615	8,390	10,445	2,302	
YoY Change (%)	-4.2	12.8	-5.3	56.8	67.9	12.3	31.4	9.3	13.6	24.5	14.5	
Margins (%)	16.7	28.4	25.0	25.7	26.3	30.2	27.8	26.9	24.3	27.9	27.1	
Interest	3	4	3	8	4	3	1	5	18	12	3	
Other Income	364	282	281	298	356	345	351	348	1,226	1,400	300	
PBT before EO Expense	1,637	2,992	2,287	2,682	2,494	3,391	2,991	2,958	9,598	11,833	2,599	
Tax	487	817	197	761	671	913	782	782	2,262	3,148	689	
Rate (%)	29.8	27.3	8.6	28.4	26.9	26.9	26.2	26.4	22.4	26.6	26.5	
Adjusted PAT	1,150	2,175	2,090	1,921	1,823	2,477	2,209	2,176	7,336	8,686	1,910	16%
YoY Change (%)	-1.1	12.5	18.8	56.1	58.6	13.9	5.7	13.3	20.5	18.4	-8.6	
Margins (%)	15.1	22.7	26.0	20.7	22.4	24.5	23.3	22.4	21.2	23.2	22.5	
One-off Expense/(Income)	-173	0	1,633	-24	0	-47	-90	0	1,436	-137	0	
Reported PAT	1,323	2,175	457	1,945	1,823	2,524	2,299	2,176	5,900	8,822	1,910	20%
Reported PAT incl disc operations	1,323	2,175	457	1,945	1,823	2,524	2,209	2,176	5,900	8,733	1,910	16%

KPIs (Consolidated)

Y/E March	FY24				FY25E				FY24	FY25E	FY25E
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE			3QE
Cost Break-up											
RM Cost (% of Sales)	38.9	37.0	39.3	39.5	36.2	38.0	37.8	37.7	38.6	37.5	37.7
Staff Cost (% of Sales)	21.7	15.2	17.6	18.6	18.6	14.9	14.1	15.6	18.1	15.7	17.3
Other Cost (% of Sales)	20.6	17.5	16.0	14.3	16.9	15.2	18.3	18.1	17.0	17.1	15.8
Gross Margins (%)	61.1	63.0	60.7	60.5	63.8	62.0	62.2	62.3	61.4	62.5	62.3
EBITDA Margins (%)	18.9	30.3	27.1	27.7	28.3	31.8	29.8	28.7	26.3	29.7	29.2
EBIT Margins (%)	16.7	28.4	25.0	25.7	26.3	30.2	27.8	26.9	24.3	27.9	27.1

E: MOFSL Estimates

Focus on brand building and expansion of adult vaccination program to drive growth

- GLXO is witnessing strong demand in its specialty portfolio, comprising Nucala, and Trelegy.
- It plans to continue to invest in building newer capabilities to improve reach and access for its specialty portfolio. It is focusing on launching more specialty products in the ovarian and endometrial cancer drugs in 1HFY26.
- Further GLXO has 16 drugs under clinical trials in India and plans to launch innovative products over the next 12-18 months.
- The company plans to drive operational efficiency and explore innovative solutions, including an omnichannel strategy, to expand reach and coverage to the target segments.
- Volume growth in generic business would be sustained going forward due to strong brand equity, improved MR productivity, and the launch of line extensions in big brands.
- The vaccine segment reported 15% YoY growth, driven by strong growth items like Boostrix, Variritix, and Fluarix. In addition, GLXO is intensifying its efforts to increase adult immunization through campaigns, awareness drives, and


increasing touchpoints through medical practitioners and hospitals, which will propel Shingrix's growth.

- Accordingly, we expect an 11% revenue CAGR on overall basis to INR46.5b over FY25-27.

Reiterate Neutral


- We raise our earnings estimates by 2%/5%/7% for FY25/FY26/FY27 to factor in a) differentiated launches in cancer therapy, b) scale-up of vaccines business, c) enhanced efforts to boost vaccine prospects. We value GLXO at 33x 12M forward earnings to arrive at a TP of INR2,170.
- Compared to a 9% EBITDA CAGR over FY22-24, we expect GLXO to deliver a 19% EBITDA CAGR over FY25-27, driven by niche launches, market share gain and enhanced reach. In addition to vaccines, GLXO would also be introducing innovative drugs to treat endometrial and ovarian cancer. However, the current valuation captures the earnings upside. Maintain Neutral.

Exhibit 1: P/E chart



Source: MOFSL, Company, Bloomberg


Exhibit 2: EV/EBITDA chart



Source: MOFSL, Company, Bloomberg


Story in charts

Exhibit 3: Sales grew 18% YoY in 3QFY25




Source: Company, MOFSL

Exhibit 4: EBITDA margin improved 270bp YoY in 3QFY25




Source: Company, MOFSL

Exhibit 5: Revenue CAGR of 11% estimated over FY25-27




Source: Company, MOFSL

Exhibit 6: Expect margins to improve over FY25-27




Source: Company, MOFSL

Exhibit 7: Earnings CAGR of ~16% estimated over FY25-27



Source: Company, MOFSL

Exhibit 8: Cash likely to be distributed to stakeholders



Source: Company, MOFSL

Financials and valuations

Income Statement									(INR m)
Y/E December	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Net Sales	31,281	32,244	29,256	32,780	32,517	34,537	37,467	41,588	46,579
Change (%)	8.0	3.1	-9.3	12.0	-0.8	6.2	8.5	11.0	12.0
EBITDA	6,008	6,573	5,981	7,639	8,043	9,087	11,141	12,851	14,769
Change (%)	18.8	9.4	-9.0	27.7	5.3	13.0	22.6	15.3	14.9
Margin (%)	19.2	20.4	20.4	23.3	24.7	26.3	29.7	30.9	31.7
Depreciation	486	827	786	682	658	697	696	737	694
EBIT	5,522	5,746	5,195	6,957	7,385	8,390	10,445	12,113	14,075
Int. and Fin. Charges	6	63	35	20	18	18	12	12	11
Other Income - Rec.	1,023	790	1,106	758	1,007	1,226	1,400	1,450	1,520
PBT	6,540	6,472	6,266	7,695	8,374	9,598	11,833	13,551	15,584
Tax	2,373	1,698	1,667	1,953	2,288	2,262	3,148	3,550	3,896
Tax Rate (%)	36.3	26.2	26.6	25.4	27.3	23.6	26.6	26.2	25.0
Adj PAT	4,167	4,775	4,596	5,739	6,086	7,336	8,686	10,001	11,688
Change (%)	25.2	14.6	-3.8	24.9	6.0	20.5	18.4	15.1	16.9
One-off income (net of tax)	-21	-3,843	-1,726	116	10	-1,436	47	0	0
Reported PAT Before Disc. Operations	4,454	932	2,873	5,858	6,096	5,900	8,733	10,001	11,688

Balance Sheet									(INR m)
Y/E December	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Equity Share Capital	1,694	1,694	1,694	1,694	1,694	1,694	1,694	1,694	1,694
Reserves	19,687	16,495	13,280	24,919	16,923	16,065	20,122	25,448	32,460
Capital Reserve	17	17	17	17	17	17	17	17	17
Net Worth	21,398	18,206	14,991	26,630	18,634	17,776	21,833	27,159	34,171
Loans	2	0	0	0	0	0	0	0	0
Capital Employed	21,400	18,206	14,991	26,630	18,634	17,777	21,834	27,159	34,171
Gross Block	5,590	10,190	6,740	7,740	8,740	8,131	8,631	9,131	9,631
Less: Accum. Deprn.	1,278	2,105	2,891	3,573	4,230	4,927	5,623	6,360	7,054
Net Fixed Assets	4,300	7,566	3,843	3,294	4,510	3,204	3,008	2,771	2,577
Capital WIP	10,026	1,201	132	305	203	139	139	139	139
Investments	17	15	14	3,668	5,194	8,141	8,141	8,141	8,141
Curr. Assets	24,148	21,469	26,114	37,934	23,245	22,619	25,824	33,228	43,130
Inventory	4,865	4,830	5,467	5,347	4,600	5,251	5,807	6,613	7,546
Account Receivables	1,205	998	2,156	2,052	1,924	2,221	2,435	2,870	3,493
Cash & Bank Balance	11,714	10,832	11,580	24,845	11,559	10,632	10,462	15,844	22,542
Others	6,364	4,808	6,911	5,689	5,162	4,516	7,119	7,902	9,549
Curr. Liability & Prov.	17,713	13,149	16,143	19,703	15,853	17,789	16,742	18,583	21,279
Account Payables	13,642	7,763	11,006	13,801	9,127	11,379	8,992	9,981	11,645
Provisions	4,071	5,386	5,137	5,902	6,726	6,410	7,750	8,602	9,634
Net Current Assets	6,435	8,319	9,971	18,231	7,392	4,830	9,082	14,644	21,851
Deferred Tax Assets	622	1105	1031	1132	1336	1462	1463	1463	1463
Appl. of Funds	21,400	18,206	14,991	26,630	18,634	17,776	21,834	27,159	34,171

E: MOFSL Estimates

Financials and valuations

Ratios

Y/E December	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
EPS	24.6	28.2	27.1	33.9	35.9	43.3	51.3	59.0	69.0
Cash EPS	27.5	33.1	31.8	37.9	39.8	47.4	55.4	63.4	73.1
BV/Share	126.3	107.5	88.5	157.2	110.0	104.9	128.9	160.3	201.7
DPS	20.0	20.0	30.0	30.0	20.0	22.0	24.0	24.0	24.0
Payout (%)	97.9	85.4	133.1	106.6	67.0	61.1	56.3	48.9	41.9

Valuation

P/E	82.3	71.8	74.6	59.8	56.4	46.8	39.5	34.3	29.4
Cash P/E	73.7	61.2	63.7	53.4	50.9	42.7	36.6	31.9	27.7
P/BV	16.0	18.8	22.9	12.9	18.4	19.3	15.7	12.6	10.0
EV/Sales	10.9	10.6	11.7	9.9	10.4	9.7	8.9	7.9	6.9
EV/EBITDA	56.9	52.1	57.2	42.6	41.9	36.8	30.1	25.6	21.9
Dividend Yield (%)	1.0	1.0	1.5	1.5	1.0	1.1	1.2	1.2	1.2

Return Ratios (%)

RoE	19.5	26.2	30.7	21.6	32.7	41.3	39.8	36.8	34.2
RoCE	19.9	24.3	27.9	27.7	26.9	40.4	43.9	40.9	38.1

Working Capital Ratios

Fixed Asset Turnover (x)	8.3	5.4	5.1	9.2	8.3	9.0	12.1	14.4	17.4
Debtor (Days)	14	11	27	23	22	23	24	25	27
Inventory (Days)	57	55	68	60	52	55	57	58	59
Creditor days	159	88	137	154	102	120	88	88	91

Leverage Ratio

Debt/Equity	-0.5	-0.6	-0.8	-0.9	-0.6	-0.6	-0.5	-0.6	-0.7
-------------	------	------	------	------	------	------	------	------	------

Cash Flow Statement

(INR m)

Y/E December	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Oper. Profit/(Loss) bef. Tax	5,987	2,730	4,255	7,755	8,053	9,087	11,141	12,851	14,769
Interest/Div. Recd.	1,023	790	1,106	758	1,007	1,226	1,400	1,450	1,520
Direct Taxes Paid	-1,958	-2,180	-1,594	-2,053	-2,491	-2,389	-3,149	-3,550	-3,896
(Inc)/Dec in WC	-619	-2,766	-904	5,006	-2,447	1,635	-4,422	-181	-508
CF from Operations	4,434	-1,427	2,864	11,465	4,121	9,559	4,970	10,569	11,885
EO expense	-21	-3,843	-1,726	116	10	0	0	0	0
CF frm Op. incl EO exp.	4,095	4,905	5,384	12,143	4,111	9,559	4,970	10,569	11,885
(inc)/dec in FA	-2,367	4,225	4,519	-1,173	-898	673	-500	-500	-500
Free Cash Flow	1,707	5,287	8,177	11,086	3,223	10,232	4,470	10,069	11,385
(Pur)/Sale of Investments	1	2	1	-3,655	-1,526	173	0	0	0
CF from investments	-1,535	-568	4,180	-4,055	-2,424	846	-500	-500	-500
Change in Equity capital	847	-	0	0	0	0	0	0	0
Inc/(Dec) in Debt	-4	-2	0	0	0	0	0	0	0
Interest Paid	-6	-63	-35	-20	-18	-18	-12	-12	-11
Dividend Paid	-4,080	-4,078	-6,117	-6,117	-4,078	-4,486	-4,894	-4,894	-4,894
CF from Fin. Activity	-3,583	-4,276	-6,560	-9,278	-14,975	-6,774	-4,690	-4,690	-4,689
Inc/Dec of Cash	-1,023	60	3,004	-1,190	-13,287	3,631	-219	5,380	6,697
Add: Beginning Balance	2,011	988	1,048	4,052	2,862	-10,425	-6,794	-7,014	-1,634
Closing Balance	988	1,048	4,052	2,862	-10,425	-6,794	-7,014	-1,634	5,063
Bank balances other than cash	10,725	9,784	7,528	21,983	21,983	21,983	21,983	21,983	21,983
Closing Balance	11,714	10,832	11,580	24,845	11,559	10,632	10,462	15,844	22,542

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://online-reports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered/qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:
financial interest in the subject company

- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal,

Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dp@grievances@motilaloswal.com.